– USA, CA – Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Dr. Charles Homcy, who will remain on the Board.
About Hervé Hoppenot
Hervé Hoppenot brings over three decades of experience in therapeutic development and commercial leadership to the Board. He most recently served as CEO of Incyte Corporation from 2014 to 2025 and as Chairman of Incyte from 2015 to 2025, following his appointment to the Board of Directors in 2014. Before Incyte, he held senior positions at Novartis, including President of Novartis Oncology, CCO, and Head of Global Product Strategy & Scientific Development, as well as SVP and Head of Global Marketing for Novartis Oncology.
Earlier in his career, Hervé Hoppenot advanced through a series of leadership roles at Aventis, including VP of U.S. Oncology.
Hervé Hoppenot serves on the boards of Incyte, Laboratoires Pierre Fabre, N-Power Medicine, and Bicycle Therapeutics.
Hervé Hoppenot holds a degree from ESSEC Business School in France.
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small-molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco.
For more: https://mazetx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.